Lerisetron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lerisetron
Lerisetron.png
Systematic (IUPAC) name
1-benzyl-2-piperazin-1-yl-1H-benzimidazole
Clinical data
Legal status
?
Identifiers
CAS number 143257-98-1 N
ATC code None
PubChem CID 65997
ChemSpider 59389 YesY
UNII Q36R82SXRG YesY
ChEMBL CHEMBL56900 YesY
Synonyms Lerisetron
Chemical data
Formula C18H20N4 
Mol. mass 292.378 g/mol
 N (what is this?)  (verify)

Lerisetron (F-0930-RS) is a drug which acts as an antagonist at the 5HT3 receptor[1] It is a potent antiemetic[2][3] and is currently in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]


References[edit]

  1. ^ Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. 1997 Feb 14;40(4):586-93. PMID 9046349
  2. ^ Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998;37(7-8):759-63. PMID 10050999
  3. ^ Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittelforschung. 2002;52(9):689-94. PMID 12404884
  4. ^ Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. 2003 Jul;4(7):874-7. PMID 14619411